Ocugen Inc (OCGN)
NASDAQ:OCGN
Want to see OCGN full AI Analyst Report?
OCGN Stock Chart & Stats
$1.99
-$0.04(-4.99%)
At close: 4:00 PM EST
$1.99
-$0.04(-4.99%)
Day’s Range― - ―
52-Week Range$0.90 - $2.73
Previous CloseN/A
Volume1.89M
Average Volume (3M)6.60M
Market Cap
$419.77M
Enterprise Value$417.82M
Total Cash (Recent Filing)$31.86M
Total Debt (Recent Filing)$33.30M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Jul 31, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding338,521,850
10 Day Avg. Volume7,418,127
30 Day Avg. Volume6,603,639
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)-33.31
Price to Sales (P/S)91.83
P/FCF Ratio-7.09
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue93.58
Enterprise Value/Gross Profit93.58
Enterprise Value/Ebitda-6.51
Forecast
1Y Price Target
$9.67Price Target Upside385.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.22
Revenue Forecast (FY)$4.38M
Bulls Say, Bears Say
Bulls Say
Late-stage Pipeline ProgressCompletion of pivotal enrollment and positive 12-month Phase 2 efficacy/safety data materially de-risks core programs. These advances support planned registrational trials and regulatory filings, increasing the likelihood of future approvals and sustainable commercial revenue if phase results translate to labeling.
Gene-agnostic PlatformA gene-agnostic AAV5 modifier approach provides scalable applicability across many retinal indications, expanding addressable markets and enabling development efficiencies. If clinical benefit and safety are durable, the platform can support multiple programs and long-term competitive differentiation versus mutation-specific therapies.
Extended Cash RunwayThe convertible notes financing improved near-term liquidity, retired higher-cost debt, and management expects runway into 2028. This structural extension reduces immediate refinancing pressure, funds late-stage trials and regulatory activities, and provides time to advance programs toward value-creating inflection points.
Bears Say
Weak Cash GenerationPersistently negative operating and free cash flows signify ongoing cash burn and inability to self-fund development. This structural shortfall forces repeated external financing, constrains discretionary investment, raises dilution risk for shareholders, and limits resilience if clinical setbacks occur.
Stressed Balance SheetNegative equity, rising debt and shrinking assets indicate a weakened balance sheet and limited capital cushion. Elevated leverage reduces financial flexibility, increases refinancing and covenant risk, and can impair the company's ability to secure favorable partnerships or scale manufacturing for commercialization.
Financing And Dilution RiskThe convertible senior notes introduce potential material equity issuance and a persistent overhang. Conversion or settlement terms could dilute existing holders or require cash outflows, creating structural capital‑structure risk that affects shareholder economics and could complicate future financing or M&A negotiations.
Ocugen News
OCGN FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was $0.90 and its highest was $2.73 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is $419.77M.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is Jul 31, 2026 which is in 40 days.
How were Ocugen Inc’s earnings last quarter?
Ocugen Inc released its earnings results on May 05, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.051 by -$0.009.
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -0.05.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 338,521,850 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Ocugen Inc reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.051. Following the earnings report the stock price went down -19.459%.
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in OCGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.67 (385.76% Upside)
$9.67 (385.76% Upside)
Blogger Sentiment
Bullish
OCGN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.76%
12-Months-Change
Fundamentals
Return on Equity
-9999.00%
Trailing 12-Months
Asset Growth
-11.72%
Trailing 12-Months
Company Description
Ocugen Inc
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
OCGN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial scientific and operational progress across multiple gene‑therapy programs (OCU400, OCU410, OCU410ST) including completed Phase 3 enrollment, strong early efficacy signals (46% lesion reduction, 50% responder rate, ~two-line LLVA gain, 60% slower EZ loss), a peer‑reviewed publication, a regional licensing deal, recent capital raise, and senior hires to support commercialization. Counterbalancing these positives are a limited cash runway into 2026 (dependence on uncertain warrant exercise and future financings), rising R&D spend (~24% year) and small/preliminary datasets that require confirmatory Phase 3 results. Overall, the highlights (clinical progress, regulatory alignment, partnerships, fundraising, leadership additions) meaningfully outweigh the risks, though execution and financing remain key near‑term priorities.View all OCGN earnings summariesOCGN Stock 12 Month Forecast
Average Price Target
$9.67
▲(385.76% Upside)
Technical Analysis
Sinovac Biotech
―
XOMA Royalty Corporation
―
ADC Therapeutics
―
Monte Rosa Therapeutics
―
AbSci
―
Ownership Overview
2.65% Insiders
5.41% Mutual Funds
5.94% Other Institutional Investors
78.52% Public Companies and Individual Investors